Key result
Kampo therapy significantly improved vascular age in patients with higher-than-expected baseline vascular age, reducing the difference between vascular and calendar age from approximately 10 to 7 years after 1 month of treatment.
Why the study?
Does Kampo therapy improve Vascular Age measured by SDPTG in patients?
Observational (n=133)
No
Does Kampo therapy improve Vascular Age measured by SDPTG in patients?
Kampo therapy may improve vascular age in patients with elevated baseline vascular age, potentially through modulation of autonomic nervous system function.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
KIMURA et al. (2005) conducted an observational in Patients receiving Kampo therapy (n=133). Kampo therapy vs. Healthy controls / Baseline was evaluated on Difference between vascular age and calendar age (VA - Age) (p=<0.001). Kampo therapy significantly improved vascular age in patients with higher-than-expected baseline vascular age, reducing the difference between vascular and calendar age from approximately 10 to 7 years after 1 month of treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: